CLINICAL STAGE IV GASTRIC CANCER AJCC V8
Clinical trials for CLINICAL STAGE IV GASTRIC CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE IV GASTRIC CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE IV GASTRIC CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New way to deliver chemo shows promise for stomach cancer patients
Disease control OngoingThis early-phase study is testing a chemotherapy drug called paclitaxel, given directly into the abdomen, for people with advanced stomach or gastroesophageal cancer that has spread to the lining of the abdomen. The main goal is to find the safest dose and understand side effects…
Matched conditions: CLINICAL STAGE IV GASTRIC CANCER AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 03:26 UTC
-
New drug combo targets tough cancers in early trial
Disease control OngoingThis early-phase trial tests a new drug (BAY 1895344) combined with standard chemotherapy in people with advanced solid tumors, especially bladder cancer. The goal is to find the safest dose and see how well the combination works. About 74 adults with cancers like lung, bladder, …
Matched conditions: CLINICAL STAGE IV GASTRIC CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Radiation boost may extend life for limited-spread stomach and esophageal cancers
Disease control OngoingThis study tests whether adding radiation therapy to standard chemotherapy helps people with HER2 negative esophageal or stomach cancer that has spread to only a few spots in the body. About 314 participants will receive either chemotherapy alone or chemotherapy plus radiation. T…
Matched conditions: CLINICAL STAGE IV GASTRIC CANCER AJCC V8
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
Stomach cancer combo fails to shrink tumors in early trial
Disease control OngoingThis study tested a combination of two drugs, berzosertib and irinotecan, in 17 people with advanced stomach or gastroesophageal junction cancer that had a specific genetic change (TP53 mutation) and was no longer responding to other treatments. The goal was to see if the combina…
Matched conditions: CLINICAL STAGE IV GASTRIC CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
Two-Drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a combination of two drugs—sonidegib and pembrolizumab—in people with advanced solid tumors that have spread. The goal is to find the safest dose of sonidegib when used with pembrolizumab and to see if the pair can shrink tumors. About 36 adults with …
Matched conditions: CLINICAL STAGE IV GASTRIC CANCER AJCC V8
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 08, 2026 12:00 UTC
-
New combo therapy targets hard-to-treat HER2 cancers in early trial
Disease control OngoingThis early-phase trial tests a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a cell-growth blocker)—in people with advanced solid tumors that have a HER2 mutation. The study first finds the safest dose, then compares the combo against…
Matched conditions: CLINICAL STAGE IV GASTRIC CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 06, 2026 16:02 UTC
-
Massive biobank aims to unlock Cancer's secrets
Knowledge-focused OngoingThis study collects tissue and blood samples, along with medical information, from 1,600 people with various advanced cancers. Researchers will store and study these samples over time to learn how cancer changes and why some treatments stop working. The goal is to improve future …
Matched conditions: CLINICAL STAGE IV GASTRIC CANCER AJCC V8
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated May 07, 2026 18:40 UTC